Detail publikace

Metallothionein Isoforms as Double Agents - Their Roles in Carcinogenesis, Cancer Progression and Chemoresistance

MERLOS RODRIGO, M. JIMENEZ JIMENEZ, A. HADDAD, Y. BODOOR, K. ADAM, P. KŘÍŽKOVÁ, S. HEGER, Z. ADAM, V.

Originální název

Metallothionein Isoforms as Double Agents - Their Roles in Carcinogenesis, Cancer Progression and Chemoresistance

Typ

článek v časopise ve Web of Science, Jimp

Jazyk

angličtina

Originální abstrakt

Metallothioneins (MTs) are small cysteine-rich intracellular proteins with four major isoforms identified in mammals, designated MT-1 through MT-4. The best known biological functions of MTs are their ability to bind and sequester metal ions as well as their active role in redox homeostasis. Despite these protective roles, numerous studies have demonstrated that changes in MT expression could be associated with the process of carcinogenesis and participation in cell differentiation, proliferation, migration, and angiogenesis. Hence, MTs have the role of double agents, i.e., working with and against cancer. In view of their rich biochemical properties, it is not surprising that MTs participate in the emergence of chemoresistance in tumor cells. Many studies have demonstrated that MT overexpression is involved in the acquisition of resistance to anticancer drugs including cisplatin, anthracyclines, tyrosine kinase inhibitors and mitomycin. The evidence is gradually increasing for a cellular switch in MT functions, showing that they indeed have two faces: protector and saboteur. Initially, MTs display anti-oncogenic and protective roles; however, once the oncogenic process was launched, MTs are utilized by cancer cells for progression, survival, and contribution to chemoresistance. The duality of MTs can serve as a potential prognostic/diagnostic biomarker and can therefore pave the way towards the development of new cancer treatment strategies. Herein, we review and discuss MTs as tumor disease markers and describe their role in chemoresistance to distinct anticancer drugs.

Klíčová slova

Anthracyclines; Cancer; Chemoresistance; Chemotherapeutics; Cisplatin; Metallomics; Metallothioneins; Tyrosine kinase inhibitors

Autoři

MERLOS RODRIGO, M.; JIMENEZ JIMENEZ, A.; HADDAD, Y.; BODOOR, K.; ADAM, P.; KŘÍŽKOVÁ, S.; HEGER, Z.; ADAM, V.

Vydáno

30. 9. 2020

Nakladatel

Elsevier

ISSN

1368-7646

Periodikum

DRUG RESISTANCE UPDATES

Ročník

52

Číslo

1

Stát

Spojené království Velké Británie a Severního Irska

Strany od

1

Strany do

13

Strany počet

13

URL

https://www.sciencedirect.com/science/article/pii/S1368764620300182

Plný text v Digitální knihovně

http://hdl.handle.net/11012/195646

BibTex

@article{BUT164638,
  author="MERLOS RODRIGO, M. and JIMENEZ JIMENEZ, A. and HADDAD, Y. and BODOOR, K. and ADAM, P. and KŘÍŽKOVÁ, S. and HEGER, Z. and ADAM, V.",
  title="Metallothionein Isoforms as Double Agents - Their Roles in Carcinogenesis, Cancer Progression and Chemoresistance",
  journal="DRUG RESISTANCE UPDATES",
  year="2020",
  volume="52",
  number="1",
  pages="1--13",
  doi="10.1016/j.drup.2020.100691",
  issn="1368-7646",
  url="https://www.sciencedirect.com/science/article/pii/S1368764620300182"
}